Treatment with Lanreotide Depot Following Octreotide Long-Acting Release Among Patients with Gastroenteropancreatic Neuroendocrine Tumors

Objective: To examine patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who receive sequential treatment with somatostatin analogs. Materials and Methods: This retrospective chart review examined lanreotide depot/autogel tolerability and efficacy among GEP-NET patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Saif, Muhammad Wasif, Fu, Julie, Smith, Melissa H., Weinstein, Barbara, Relias, Valerie, Daly, Kevin P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371583/
https://www.ncbi.nlm.nih.gov/pubmed/30788459
http://dx.doi.org/10.1089/pancan.2018.0013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371583/
https://www.ncbi.nlm.nih.gov/pubmed/30788459
http://dx.doi.org/10.1089/pancan.2018.0013

Ejemplares similares